Sugi Predict

Sugi Predict / Compounds / SCHEMBL4767261

SCHEMBL4767261

SCHEMBL4767261

CC(C)(C)OC(=O)N1CCC(c2c[nH]c3ccncc23)CC1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 8/20 0.53
▸ KDM4E B2RXH2 2/20 0.49
▸ BRD4 O60885 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ CREBBP Q92793 1/20 0.49
▸ JAK2 O60674 1/20 0.47
▸ JAK1 P23458 1/20 0.47
▸ TYK2 P29597 1/20 0.47
▸ JAK3 P52333 1/20 0.47
▸ NAMPT P43490 3/20 0.46
▸ MAPT P10636 1/20 0.46
▸ THRB P10828 1/20 0.46
▸ CCR2 P41597 2/20 0.45
▸ HSD11B1 P28845 1/20 0.44
▸ CTSS P25774 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12327686 0.91 GPR119 (0.53) GPR119KDM4EBRD4ALDH1A1POLB
SCHEMBL31001677 0.91 GPR119 (0.53) GPR119KDM4EBRD4ALDH1A1POLB
SCHEMBL5750697 0.85 CTSS (0.43) GPR119KDM4EBRD4ALDH1A1POLB
SCHEMBL557776 0.84 KDM4E (0.70) GPR119KDM4EBRD4ALDH1A1POLB
SCHEMBL18324777 0.84 KDM4E (0.69) KDM4EBRD4ALDH1A1POLBCREBBP
Hydrochloric Acid SCHEMBL1703924 0.83 KDM4E (0.68) GPR119KDM4EBRD4ALDH1A1POLB
SCHEMBL8618496 0.81 CYP1A2 (0.63) KDM4EBRD4ALDH1A1POLBCREBBP
SCHEMBL24377767 0.81 KDM4E (0.47) GPR119KDM4EBRD4ALDH1A1POLB
SCHEMBL16610331 0.81 KDM4E (0.47) GPR119KDM4EBRD4ALDH1A1POLB
SCHEMBL6212815 0.80 HTR1D (0.62) KDM4EBRD4ALDH1A1POLBCREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1497292-B1 AZAINDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS ALMIRALL PRODESFARMA SA (ES) 2006-06-14 — — EP claimed
CN-107001332-B Piperidine derivatives 豪夫迈·罗氏有限公司 2020-05-15 — — CN disclosed
US-20190307737-A1 NOVEL PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2019-10-10 — — US disclosed
EP-3227282-B1 NOVEL PIPERIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2019-04-03 — — EP disclosed
US-10172843-B2 Piperidine derivatives HOFFMANN-LA ROCHE INC. (US) 2019-01-08 — — US disclosed
EP-3227282-A1 NOVEL PIPERIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2017-10-11 — — EP disclosed
US-20170266175-A1 NOVEL PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-09-21 — — US disclosed
WO-2016087352-A1 NOVEL PIPERIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2016-06-09 — — WO disclosed
EP-1315492-B1 USE OF SUBSTITUTED PYRAZOLES FOR THE TREATMENT OF ALLERGIES ORTHO MCNEIL PHARM INC (US) 2008-07-30 — — EP disclosed
US-7265102-B2 Substituted pyrazoles ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2007-09-04 — — US disclosed
US-20030225063-A1 Substituted pyrazoles ORTHO MCNEIL PHARMACEUTICAL, INC. 2003-12-04 — — US disclosed
US-20030225062-A1 Substituted pyrazoles ORTHO MCNEIL PHARMACEUTICAL, INC. 2003-12-04 — — US disclosed
US-6635633-B2 Substituted pyrazoles ORTHO-PHARMACEUTICAL, INC. 2003-10-21 — — US disclosed
US-6579896-B2 Immunology response; autoimmune disease ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-06-17 — — US disclosed
EP-1315492-A2 A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES Ortho McNeil Pharmaceutical, Inc. (US) 2003-06-04 — — EP disclosed
EP-1309592-A2 SUBSTITUTED PYRAZOLES Ortho-McNeil Pharmaceutical, Inc. (US) 2003-05-14 — — EP disclosed
US-20020147189-A1 Method for treating allergies using substituted pyrazoles ORTHO MCNEIL PHARMACEUTICAL, INC. 2002-10-10 — — US disclosed
US-20020040019-A1 Substituted pyrazoles ORTHO MCNEIL PHARMACEUTICAL, INC. 2002-04-04 — — US disclosed
WO-2002020013-A2 A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2002-03-14 — — WO disclosed
WO-2002014317-A2 SUBSTITUTED PYRAZOLES ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2002-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225062-A1 Substituted pyrazoles CTSS, CTSZ, CTSV GPR119 2768/4885KDM4E 2928/4885BRD4 866/4885
US-20020040019-A1 Substituted pyrazoles CTSS, CTSZ, CTSV GPR119 2768/4885KDM4E 2928/4885BRD4 866/4885
US-20190307737-A1 NOVEL PIPERIDINE DERIVATIVES ADORA1, ADRA1D, ADORA2B GPR119 742/4885KDM4E 3394/4885BRD4 675/4885
US-20170266175-A1 NOVEL PIPERIDINE DERIVATIVES ADORA1, ADRA1D, ADORA2B GPR119 742/4885KDM4E 3394/4885BRD4 675/4885
US-20030225063-A1 Substituted pyrazoles CTSS, CTSZ, CTSV GPR119 2768/4885KDM4E 2928/4885BRD4 866/4885
US-20020147189-A1 Method for treating allergies using substituted pyrazoles TSLP, IL33, HRH2 GPR119 4518/4885KDM4E 2491/4885BRD4 140/4885
US-10172843-B2 Piperidine derivatives ADRA1D, ADORA1, ADRA1A GPR119 1707/4885KDM4E 3191/4885BRD4 1014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.